These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Comparison of BL-S786 with cephalothin, cefamandole and cefoxitin in vitro and in treatment of experimental infections in mice. Goering RV; Sanders CC; Sanders W J Antibiot (Tokyo); 1978 Apr; 31(4):363-72. PubMed ID: 306989 [TBL] [Abstract][Full Text] [Related]
6. The in vitro spectrum of the cephalosporins. Washington JA Mayo Clin Proc; 1976 Apr; 51(4):237-50. PubMed ID: 1263595 [TBL] [Abstract][Full Text] [Related]
7. Serum and tissue concentrations of cefoxitin and cefamandole in women undergoing hysterectomy. French MA; Quintiliani R; Nightingale CH; Russo JN Obstet Gynecol; 1983 Jan; 61(1):42-7. PubMed ID: 6823348 [TBL] [Abstract][Full Text] [Related]
8. In vitro comparison of cefoxitin, cefamandole, cephalexin, and cephalothin. Eickhoff TC; Ehret JM Antimicrob Agents Chemother; 1976 Jun; 9(6):994-9. PubMed ID: 938029 [TBL] [Abstract][Full Text] [Related]
9. Review of the new second-generation cephalosporins: cefonicid, ceforanide, and cefuroxime. Tartaglione TA; Polk RE Drug Intell Clin Pharm; 1985 Mar; 19(3):188-98. PubMed ID: 3884304 [TBL] [Abstract][Full Text] [Related]
10. Correlation of in vitro susceptibility with in vivo efficacy in mice for cefoxitin in comparison with cephalosporins. Miller AK; Celozzi E; Pelak BA; Birnbaum J; Stapley EO J Antimicrob Chemother; 1979 Sep; 5(5):569-79. PubMed ID: 315403 [TBL] [Abstract][Full Text] [Related]
11. The activity of cephalosporins on beta-lactamase-producing Neisseria gonorrhoeae. Phillips I; Shannon K Scand J Infect Dis Suppl; 1978; (13):23-6. PubMed ID: 98833 [TBL] [Abstract][Full Text] [Related]
12. Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use. Brogden RN; Heel RC; Speight TM; Avery GS Drugs; 1979 Jan; 17(1):1-37. PubMed ID: 369806 [TBL] [Abstract][Full Text] [Related]
13. Cefuroxime, cefamandole, cefoxitin, and cephalothin in vitro susceptibility tests: reassessment of the "class representative" concept, confirmation of disk interpretive criteria, and proposed quality control guidelines. Barry AL; Jones RN; Thornsberry C Am J Clin Pathol; 1983 Aug; 80(2):182-9. PubMed ID: 6881092 [TBL] [Abstract][Full Text] [Related]
14. Update on drug therapy. IV. Parenteral cephalosporins. Dahl SL; Elenbaas J; Hamburger S J Am Med Womens Assoc (1972); 1980 Apr; 35(4):99-100, 107-8. PubMed ID: 6246160 [No Abstract] [Full Text] [Related]
15. Comparative in-vitro activity of cefamandole, cefoxitin, cefuroxime and cephalothin. Brorson JE; Norrby R Scand J Infect Dis Suppl; 1978; (13):88-93. PubMed ID: 278150 [No Abstract] [Full Text] [Related]
17. Cefonicid: a long-acting, second-generation cephalosporin. Antimicrobial activity, pharmacokinetics, clinical efficacy and adverse effects. Pontzer RE; Kaye D Pharmacotherapy; 1984; 4(6):325-33. PubMed ID: 6393074 [TBL] [Abstract][Full Text] [Related]
18. Comparative in vivo efficiency of cefamandole and cefoxitin against Bacteroides fragilis. Bergeron MG; Gauvreau L; Nguyen BM Scand J Infect Dis Suppl; 1980; suppl 25():60-5. PubMed ID: 6937954 [TBL] [Abstract][Full Text] [Related]
19. The effect of beta-lactamase stability, penetration, and target affinity on the activity of cefazolin, cefamandole, cefoxitin, and cefuroxime. Harper PB Clin Ther; 1984; 6(3):310-24. PubMed ID: 6609771 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of cefonicid sodium versus cefoxitin sodium for the prevention of postoperative infections after nonelective cesarean section. Briggs GG; Moore BR; Bahado-Singh R; Lange S; Bogh P; Garite TJ Clin Pharm; 1987 Sep; 6(9):718-21. PubMed ID: 3119278 [No Abstract] [Full Text] [Related] [Next] [New Search]